The review, published in Frontiers in Radiology, focuses primarily on immediate hypersensitivity reactions occurring within one hour of administration, the terminology used by current ACR and ESUR guidance. Some cited studies used wider windows of up to six hours, limiting direct comparisons. With roughly 50 million contrast-enhanced MRI examinations performed worldwide each year, even uncommon reactions create a growing absolute clinical burden. Immediate allergy-like events occur at an estimated rate of about nine per 10,000 administrations, while severe reactions occur near 0.5 per 10,000. Re-exposure after an initial reaction carries a markedly higher risk, making the choice of what to administer next a central safety decision in radiology practice.

Corticosteroid and antihistamine premedication was borrowed from protocols developed for iodinated contrast media, especially older high-osmolar products with greater anaphylactoid potential, rather than being validated with gadolinium-specific immunological data. A meta-analysis by Walker and colleagues found breakthrough hypersensitivity in 39% of fully premedicated patients, with a 95% confidence interval of 30% to 49%. The rate was similar across structural classes, at 36% for macrocyclic agents and 31% for protein-binding linear ionic agents. These observational estimates do not prove that premedication causes failure, but they show that it cannot reliably prevent recurrence. Prospective and retrospective studies also found no clear additional benefit from adding premedication when patients were already being switched to a structurally different agent. The review describes premedication as an evidence-limited adjunct rather than a routine first-line strategy.

The immunological reasons for changing agents are more compelling than the rationale for reflexive steroid prophylaxis. Gadolinium-based contrast agents are chelated complexes with distinct protein-binding, ionicity and dissociation characteristics. Immediate reactions may involve IgE-mediated mechanisms, non-IgE-mediated mast-cell activation through MRGPRX2, or complement-related pathways. In IgE-mediated reactions, re-exposure to the same or a similar molecule can activate mast cells and basophils. Macrocyclic and linear chelates differ in geometry and protein binding, which may limit cross-reactivity, but cannot eliminate it or allow its presence or absence to be predicted reliably from chemical structure alone. The review therefore treats agent change as an evidence-informed strategy, not as proof that any particular class-switching rule is superior.

That limitation was evident in a series of 28 patients with proven gadolinium contrast allergy, in which skin-test cross-reactivity occurred in approximately 29%. Another single-center series reported cross-reactivity rates of 27.7% among macrocyclic agents, 5.5% among linear agents and 5.5% between the two classes. These small series cannot define universal risks, but they show why simply choosing an agent from the opposite structural category is not a guarantee of safety. Cross-reactivity can occur between macrocyclic agents and between macrocyclic and linear agents, while reactions involving several products make a fixed rule even less dependable. Restrictions on some linear agents because of nephrogenic systemic fibrosis and tissue-deposition concerns further complicate a simple class-switching rule. When testing is clinically indicated, the review favors identifying a molecule that the patient is shown to tolerate rather than relying on chemical category alone.

Observational comparisons point to a substantial reduction in recurrence when the culprit agent is replaced. In a six-year propensity-score-matched cohort of more than 150,000 patients, recurrence occurred in 14.3% after changing agents, compared with 36.9% after re-exposure to the same or a related agent, corresponding to an odds ratio of 0.32. A retrospective cohort of patients with prior mild reactions reported recurrence in 6.2% after changing molecular-structure class, 11.8% after switching within the same class and 25.8% after re-exposure to the culprit. A prospective single-arm trial of empiric switching found recurrence in 3.7% of patients with a documented prior immediate reaction. These studies used different definitions, populations, severity thresholds and comparators, so their percentages are not directly interchangeable, but their direction is consistent. ESUR guidance summarizes the literature as indicating approximately 75% lower recurrence when a GBCA with a different chelate structure is administered.

Severe, recurrent or otherwise uncertain reactions require more diagnostic precision than a simple structural switch. Skin testing and the basophil activation test are specialist tools for identifying culprit agents and alternatives that may be tolerated. Panel-based skin testing should include the suspected agent and candidate replacements, ideally two to six months after the reaction when sensitivity is highest. Under the EAACI and ENDA protocol, clinicians begin with undiluted prick testing and proceed to increasingly diluted intradermal testing if necessary. Reported positivity rates range from 15% to 58%, with higher rates in more severe phenotypes. Low-dose provocation using one-tenth of the usual injected dose has a reported negative predictive value of about 86%, while newer rapid protocols approximating clinical bolus administration reached 89% in the cited evidence. Drug provocation testing remains the specialist reference standard when other assessment cannot identify a safe alternative, and only skin-test-negative candidates should be challenged.

Basophil activation testing remains available only at specialized drug-allergy centers. It measures increases in CD63 and CD203c on basophils after exposure to a contrast agent outside the body. For contrast media generally, ESUR reports specificity above 90% but sensitivity only slightly above 50%, partly because basophils express little MRGPRX2. A small gadolinium-specific series reported sensitivity of approximately 68% and specificity of 93%, but the authors caution against extrapolating those estimates. A positive result can support diagnosis, whereas a negative result does not exclude sensitization. Standardization remains incomplete, and the review notes that combining BAT with skin testing may improve diagnostic yield in complex cases without by itself proving a specific non-IgE mechanism. Skin testing, BAT and provocation testing therefore occupy different roles: they identify likely sensitization, characterize basophil activation, and confirm tolerance when performed in the appropriate specialist setting.

The review’s proposed severity-stratified pathway distinguishes immediate from delayed reactions. Mild immediate events without hypoxia or hypoperfusion should be managed by switching agents without routine premedication, while moderate reactions, recurrent events or an unclear culprit history should prompt specialist referral. Moderate-to-severe immediate reactions, including anaphylaxis, airway-threatening angioedema, hypotensive syncope or severe bronchospasm with hypoxemia, should prompt acute serum tryptase measurement within one to four hours of symptom onset and a baseline sample at least 24 hours after resolution, together with referral to a drug-allergy specialist. During urgent imaging before evaluation is complete, a non-culprit agent may be administered with trained responders, intravenous access and at least 30 minutes of nursing observation. Premedication is optional in this narrow emergency setting after a severe reaction to an unidentified agent, not a routine part of the pathway.

Delayed reactions require a separate strategy because many are T-cell-mediated and may not follow the structural-class patterns observed in immediate allergy. Non-severe cutaneous delayed reactions, such as maculopapular eruptions or fixed drug eruptions, are evaluated with delayed-reading and patch testing, preferably six months or more after recovery. The basophil activation test and immediate-reading skin tests are not applicable to these phenotypes, while provocation testing may be considered in selected cases at specialist centers. Confirmed severe cutaneous adverse reactions are different: current guidance reserves lifelong avoidance of all gadolinium-based contrast agents for this category, and provocation testing is contraindicated. The review notes that this recommendation comes from delayed-reaction guidance and falls outside its formally screened evidence base for immediate reactions. Overall, the evidence favors structured agent switching, allergy referral after significant reactions and robust emergency preparedness rather than reflexive corticosteroid prophylaxis, while the predominance of heterogeneous observational data limits the certainty of the proposed algorithm.

Subject of Research: Management of recurrent hypersensitivity reactions to gadolinium-based MRI contrast agents

Article Title: Rethinking gadolinium hypersensitivity management: from corticosteroid premedication to evidence-informed alternative GBCA selection

Article References: Yao, Y., & Gao, F. (2026). Rethinking gadolinium hypersensitivity management: from corticosteroid premedication to evidence-informed alternative GBCA selection. Frontiers in Radiology, 6, Article 1894050. https://doi.org/10.3389/fradi.2026.1894050

Image Credits: AI Generated

DOI: 10.3389/fradi.2026.1894050

Keywords: gadolinium contrast agents, MRI safety, hypersensitivity reactions, corticosteroid premedication, alternative agent selection, anaphylaxis, skin testing, basophil activation test, drug allergy, radiology nursing, Rethinking, gadolinium